Sale by Van Houte Hans of 10906 shares of Nurix TherapeuticsInc
| NRIX Stock | USD 19.60 0.46 2.40% |
Slightly above 55% of Nurix Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Nurix Therapeutics suggests that some traders are interested. Nurix Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Nurix Therapeutics' earnings reports, geopolitical events, and overall market trends.
Nurix |
Filed transaction by Nurix Therapeutics Inc officer. General open market or private sale of non-derivative or derivative security
Read at macroaxis.com
Nurix Therapeutics Fundamental Analysis
We analyze Nurix Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nurix Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nurix Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Nurix Therapeutics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Nurix Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Nurix Therapeutics stock to make a market-neutral strategy. Peer analysis of Nurix Therapeutics could also be used in its relative valuation, which is a method of valuing Nurix Therapeutics by comparing valuation metrics with similar companies.
Peers
Nurix Therapeutics Related Equities
| PRLD | Prelude Therapeutics | 16.19 | ||||
| KYMR | Kymera Therapeutics | 7.61 | ||||
| RLAY | Relay Therapeutics | 4.48 | ||||
| GBIO | Generation Bio | 4.21 | ||||
| ARVN | Arvinas | 2.88 | ||||
| FHTX | Foghorn Therapeutics | 2.62 | ||||
| STTK | Shattuck Labs | 1.83 | ||||
| BDTX | Black Diamond | 1.82 | ||||
| STOK | Stoke Therapeutics | 1.06 | ||||
| NKTX | Nkarta | 1.21 | ||||
| PLRX | Pliant Therapeutics | 1.25 | ||||
| LYEL | Lyell Immunopharma | 1.72 | ||||
| GLUE | Monte Rosa | 1.74 | ||||
| CCCC | C4 Therapeutics | 2.28 | ||||
| SANA | Sana Biotechnology | 7.59 |
Additional Tools for Nurix Stock Analysis
When running Nurix Therapeutics' price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.